Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTK0943)

• DTT Name: Prostaglandin G/H synthase (COX) DTT Info
• Gene Name: PTGS1

Molecule-Related Drug & Molecule List

20 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aceclofenac	DMZDF0B	Inflammation	1A00-CA43.1	Approved	[1]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[2]
Ampiroxicam	DM5BS98	Inflammation	1A00-CA43.1	Approved	[3]
Amtolmetin guacil	DMAWU35	Inflammation	1A00-CA43.1	Approved	[4]
Asasantin	DMCZIHT	Cerebrovascular ischaemia	8B1Z	Approved	[5]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[6]
Dexibuprofen	DMFYBD0	Ankylosing spondylitis	FA92.0	Approved	[7]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]
Felbinac	DMKZEIB	Arthritis	FA20	Approved	[9]
Fenoprofen	DML5VQ0	Osteoarthritis	FA00-FA05	Approved	[10]
Fosfosal	DMDIC39	Pain	MG30-MG3Z	Approved	[11]
Icosapent	DMJHN0A	Hyperglyceridemia	5C80.1	Approved	[12]
Ketorolac	DMI4EL5	Postoperative inflammation	1A00-CA43.1	Approved	[13]
Lornoxicam	DMYZFXN	Migraine	8A80	Approved	[14]
Loxoprofen gel	DMQMGXV	Inflammation	1A00-CA43.1	Approved	[15]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[16]
Morniflumate	DM9UTDE	Otitis media	AA80-AB0Z	Approved	[17]
Nepafenac	DMYK490	Osteoarthritis	FA00-FA05	Approved	[18]
Oxaprozin	DM9UB0P	Osteoarthritis	FA00-FA05	Approved	[10]
Pelubiprofen	DM8DQV9	Back pain	ME84.Z	Approved	[19]

8 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
K-103-IP	DM9J0KD	Pain	MG30-MG3Z	Phase 3	[20]
Naproxcinod	DMKP45D	Inflammation	1A00-CA43.1	Phase 3	[21]
BN82451	DMUM2KA	Parkinson disease	8A00.0	Phase 2	[22]
NCX 1022	DM4W28K	Atopic dermatitis	EA80	Phase 2	[23]
NCX-4016	DMOX1CU	Inflammation	1A00-CA43.1	Phase 2	[5]
TZI-41078	DMKJIDU	Arthritis	FA20	Phase 2	[24]
4-aminosalicylate sodium	DM4Z1CH	Inflammatory bowel disease	DD72	Phase 1	[25]
SKF-105809	DMUN7EQ	Pain	MG30-MG3Z	Phase 1	[26]

19 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Droxicam	DMRZ5D7	Inflammation	1A00-CA43.1	Withdrawn from market	[27]
Zomepirac	DM7APNJ	Pain	MG30-MG3Z	Withdrawn from market	[28]
Bermoprofen	DM7BN1A	Inflammation	1A00-CA43.1	Discontinued in Preregistration	[29]
Pirazolac	DMP6BG4	Inflammation	1A00-CA43.1	Discontinued in Preregistration	[30]
KC-764	DM1AFPW	Platelet aggregation disorder	3B62	Discontinued in Phase 3	[31]
Benzydamine	DMEQL9U	Chemotherapy or radiotherapy-induced mucositis	DA42-DA60	Discontinued in Phase 2	[32]
D-7193	DMO9HWU	Immune System disease	4A01-4B41	Discontinued in Phase 2	[33]
FS-205-397	DMJLEV7	Pain	MG30-MG3Z	Discontinued in Phase 2	[34]
NCX-701	DMWROJ5	Pain	MG30-MG3Z	Discontinued in Phase 2	[35]
PSD-508	DMR1OJM	Dysmenorrhea	GA34.3	Discontinued in Phase 2	[36]
D-1367	DMB24V7	Arthritis	FA20	Discontinued in Phase 1	[37]
Eltenac	DMWRQG7	Arthritis	FA20	Discontinued in Phase 1	[38]
F-11105	DMLRF7U	Asthma	CA23	Discontinued in Phase 1	[33]
E-5110	DMR861Q	Inflammation	1A00-CA43.1	Terminated	[39]
Florifenine	DMDVAI5	Inflammation	1A00-CA43.1	Terminated	[40]
NMI-1182	DM5IFU9	Inflammation	1A00-CA43.1	Terminated	[41]
RP-66364	DM6HJX7	Inflammation	1A00-CA43.1	Terminated	[42]
S-14080	DM759KX	Inflammation	1A00-CA43.1	Terminated	[43]
WY-28342	DMAG86C	Rheumatoid arthritis	FA20	Terminated	[44]

References

• [1] Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.
• [2] Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55.
• [3] Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006 Jul;35(7):613-7.
• [4] Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):809-18.
• [5] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [6] Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
• [7] Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64.
• [8] Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82.
• [9] A review of the effects of fenbufen and a metabolite, biphenylacetic acid, on platelet biochemistry and function. Arzneimittelforschung. 1980;30(4A):702-7.
• [10] The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
• [11] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [12] Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86.
• [13] Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32.
• [14] The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.
• [15] Comparative study of the clinical efficacy of the selective cyclooxygenase-2 inhibitor celecoxib compared with loxoprofen in patients with frozen shoulder. Mod Rheumatol. 2014 Jan;24(1):144-9.
• [16] Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.
• [17] Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9.
• [18] Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15.
• [19] Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF- B inactivation. J Cell Biochem. 2011 Dec;112(12):3594-603.
• [20] ClinicalTrials.gov (NCT02089425) An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.. U.S. National Institutes of Health.
• [21] Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert Opin Biol Ther. 2009 May;9(5):649-57.
• [22] Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97.
• [23] Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol. 2004 Nov;143(5):618-25.
• [24] Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10.
• [25] 5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis. Anticancer Res. 2012 Apr;32(4):1193-202.
• [26] Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7.
• [27] Pharmacokinetic profile of droxicam. Eur J Rheumatol Inflamm. 1991;11(4):10-4.
• [28] Effect of preischemia cyclooxygenase inhibition by zomepirac sodium on reflow, cerebral autoregulation, and EEG recovery in the cat after global ischemia. J Cereb Blood Flow Metab. 1986 Dec;6(6):691-702.
• [29] Prolongation of antipyretic action and reduction of gastric ulcerogenicity in the rat by controlled-release granules of bermoprofen, a new nonsteroidal anti-inflammatory drug. J Pharm Sci. 1991 Sep;80(9):876-80.
• [30] Differential dosing study of pirazolac, a new non-steroidal anti-inflammatory agent, in patients with rheumatoid arthritis. Curr Med Res Opin. 1985;9(8):542-7.
• [31] Clinical and preclinical pharmacology of KC-764, a novel antiplatelet agent. Nihon Rinsho. 1992 Feb;50(2):379-84.
• [32] Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
• [33] US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
• [34] FS 205-397: a new antipyretic analgesic with a paracetamol-like profile of activity but lack of acute hepatotoxicity in mice. Life Sci. 1988;43(11):905-12.
• [35] Antinociceptive effects of NCX-701 (nitro-paracetamol) in neuropathic rats: enhancement of antinociception by co-administration with gabapentin. Br J Pharmacol. 2009 September; 158(2): 601-609.
• [36] CN patent application no. 104797935, A method for prognosis and treatment of cancer metastasis.
• [37] US patent application no. 2007,0072,861, Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders.
• [38] Effect of eltenac in horses with induced endotoxaemia. Equine Vet J Suppl. 2000 Jun;(32):26-31.
• [39] Effect of E-5110, a novel non-steroidal anti-inflammatory drug, on trimethadione metabolism as an indicator of hepatic drug-oxidizing capacity in beagle dog. Xenobiotica. 1994 Mar;24(3):215-20.
• [40] A study of the novel anti-inflammatory agent florifenine topical anti-inflammatory activity and influence on arachidonic acid metabolism and neutrophil functions. Naunyn Schmiedebergs Arch Pharmacol.1995 Mar;351(3):298-304.
• [41] NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology. 2005;12(5-6):521-34.
• [42] WO patent application no. 1997,0297,75, Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist.
• [43] US patent application no. 7,022,689, 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor.
• [44] Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds. J Med Chem. 1995 Apr 28;38(9):1473-81.